Test new inhaler combo versus standard inhaler in teens
Part of Immune system & allergy, Lungs & breathing clinical trials.
This Phase 3 trial compares a triple inhaler (FF/UMEC/VI) against the usual double inhaler (FF/VI) to help control asthma symptoms and breathing tests in teens ages 12–17. It also checks how safe and tolerable the treatments are over the study period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 to 17 years old when you sign consent/assent
- You have had asthma for at least 1 year
- For at least 12 weeks before the study start, you used daily inhaled steroid plus a long-acting asthma inhaler, without changing your controller medicine for 6 weeks
- In the last year, you had an asthma flare serious enough to need a healthcare visit or a temporary treatment change from an asthma plan
- Your asthma is not well controlled despite your current inhaler, based on a questionnaire score (ACQ-6)
- Your breathing test results fit the study range (FEV1 between 40% and 90% of predicted, and it improves at least 12% after a reliever inhaler)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination inhaler (QVM149) against a standard one (Advair) in teenagers with asthma that isn't well controlled by their current medicine. It aims to see if the new inhaler works better.
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
This study tests a new combination inhaler (fluticasone propionate and albuterol) for people with asthma age 12 and older. It helps see if this inhaler works better than a placebo in controlling asthma symptoms and preventing attacks.
This Phase 3 study compares a new inhaler (QMF149: indacaterol plus mometasone) against budesonide to see which works better and is safe for children ages 6 to under 12 with asthma. You may be able to join if your child is already on a stable low-dose steroid inhaler and still has symptoms.
This study compares a three-in-one inhaler (ICS/LABA/LAMA) to a two-in-one inhaler (ICS/LABA) for adults whose asthma is not well-controlled despite using a standard two-in-one inhaler. The goal is to see if the triple inhaler improves asthma control better.
This Phase 2 study checks how glycopyrronium bromide works in children with asthma, including its safety and how well inhaler dosing is tolerated. It also uses breathing tests and inhaler technique checks to confirm your child meets key asthma and lung function requirements.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.